Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pertuzumab

View Patient Information
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis.
Synonym:2C4
2C4 antibody
monoclonal antibody 2C4
omnitarg
pertuzumab biosimilar BCD-178
pertuzumab biosimilar EG1206A
pertuzumab biosimilar HLX11
pertuzumab biosimilar HS627
pertuzumab biosimilar TQB2440
rhuMAb-2C4
rhuMAb2C4
US brand name:Perjeta
Abbreviation:MOAB 2C4
Code name:BCD-178
EG1206A
HLX11
HS627
RO4368451
TQB 2440
TQB-2440
TQB2440
TQB2440
Chemical structure:immunoglobulin G1, anti-(human V (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
Search NCI's Drug Dictionary